Aratana Therapeutics Inc (NASDAQ:PETX) – Analysts at William Blair raised their Q3 2018 EPS estimates for shares of Aratana Therapeutics in a research note issued to investors on Monday. William Blair analyst J. Kreger now expects that the biopharmaceutical company will earn ($0.08) per share for the quarter, up from their previous forecast of ($0.09). William Blair also issued estimates for Aratana Therapeutics’ Q4 2018 earnings at $0.24 EPS and FY2019 earnings at $0.42 EPS.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business had revenue of $6.16 million during the quarter, compared to analyst estimates of $6.47 million. During the same period in the prior year, the business earned ($0.38) EPS. The company’s revenue for the quarter was up 1440.0% on a year-over-year basis.

PETX has been the subject of several other reports. Jefferies Group set a $9.00 price objective on shares of Aratana Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 16th. Stifel Nicolaus restated a “hold” rating and issued a $6.00 price objective on shares of Aratana Therapeutics in a report on Monday. ValuEngine lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Thursday, November 9th. Finally, HC Wainwright assumed coverage on shares of Aratana Therapeutics in a report on Friday, November 17th. They issued a “buy” rating and a $10.00 price objective for the company. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Aratana Therapeutics presently has an average rating of “Hold” and an average price target of $8.55.

Shares of Aratana Therapeutics (NASDAQ PETX) traded up $0.06 during midday trading on Wednesday, reaching $5.43. 253,743 shares of the company’s stock traded hands, compared to its average volume of 417,625. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. Aratana Therapeutics has a 1-year low of $4.97 and a 1-year high of $8.63.

In related news, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.70, for a total value of $5,075,941.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Brent Standridge sold 10,000 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the chief operating officer now owns 70,267 shares of the company’s stock, valued at $429,331.37. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,117,032 shares of company stock valued at $6,559,891. 5.20% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. AWM Investment Company Inc. grew its position in Aratana Therapeutics by 49.4% during the 2nd quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock valued at $11,478,000 after purchasing an additional 525,000 shares during the last quarter. Teachers Advisors LLC grew its position in Aratana Therapeutics by 34.5% during the 2nd quarter. Teachers Advisors LLC now owns 72,244 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 18,526 shares during the last quarter. Janney Montgomery Scott LLC grew its position in Aratana Therapeutics by 7.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,200 shares during the last quarter. Williams Jones & Associates LLC purchased a new stake in Aratana Therapeutics during the 2nd quarter valued at about $827,000. Finally, Grandeur Peak Global Advisors LLC grew its position in Aratana Therapeutics by 40.4% during the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 538,363 shares of the biopharmaceutical company’s stock valued at $3,892,000 after purchasing an additional 155,000 shares during the last quarter. 73.76% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “William Blair Analysts Increase Earnings Estimates for Aratana Therapeutics Inc (PETX)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/20/william-blair-analysts-increase-earnings-estimates-for-aratana-therapeutics-inc-petx.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.